

SEP 16 2002

TECH CENTER 1600/2900

RECEIVED  
SEP 19 2002  
#2

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

<b>Application Number</b>	10/026,967
<b>Filing Date</b>	December 19, 2001
<b>First Named Inventor</b>	David Bebbington
<b>Group Art Unit</b>	<del>623</del> 1624
<b>Examiner Name</b>	Not Yet Assigned
<b>Attorney Docket Number</b>	VPI-00-130-2 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
TNT	A1	5,710,158	20-Jan-1998	Rhone-Poulenc Rorer Pharmaceuticals, Inc.	514	259	
TNT	A2	US 2001/0018436	30-Aug-2001	Tularik Inc.	514	217.06	

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office      Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes      No
TNT	B1		WO 00/39101 ✓	Astrazeneca UK Limited	06-Jul-2000	
TNT	B2		WO 00/21955 ✓	Zeneca Limited	20-Apr-2000	
TNT	B3		WO 02/18346 ✓	Pfizer Products Inc.	07-Mar-2002	

[illegible]

5/12/03

